Is clopidogrel as the P2Y12 inhibitor a wise choice for long-term monotherapy in patients undergoing stenting?
Publication
, Journal Article
Gurbel, PA; Tantry, US
Published in: EuroIntervention
December 3, 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
EuroIntervention
DOI
EISSN
1969-6213
Publication Date
December 3, 2021
Volume
17
Issue
11
Start / End Page
e865 / e866
Location
France
Related Subject Headings
- Receptors, Purinergic P2Y12
- Purinergic P2Y Receptor Antagonists
- Platelet Aggregation Inhibitors
- Percutaneous Coronary Intervention
- Humans
- Clopidogrel
- 3201 Cardiovascular medicine and haematology
- 0104 Statistics
Citation
APA
Chicago
ICMJE
MLA
NLM
Gurbel, P. A., & Tantry, U. S. (2021). Is clopidogrel as the P2Y12 inhibitor a wise choice for long-term monotherapy in patients undergoing stenting? EuroIntervention, 17(11), e865–e866. https://doi.org/10.4244/EIJV17I11A144
Published In
EuroIntervention
DOI
EISSN
1969-6213
Publication Date
December 3, 2021
Volume
17
Issue
11
Start / End Page
e865 / e866
Location
France
Related Subject Headings
- Receptors, Purinergic P2Y12
- Purinergic P2Y Receptor Antagonists
- Platelet Aggregation Inhibitors
- Percutaneous Coronary Intervention
- Humans
- Clopidogrel
- 3201 Cardiovascular medicine and haematology
- 0104 Statistics